Loading…
Loading…
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
IDNA jumped 13.53% in one day on 2.8x average volume after three catalysts, including Moderna's and Merck's positive Phase 3 INTerpath-001 data. IDNA trades at a 14.90x forward P/E, implying a 6.7% theoretical earnings yield. Closing the valuation gap with XBI's forward multiple would mechanically add about 29.5% to IDNA's price as a one-time re-rating.
iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 6,747 shares, a growth of 428.3% from the December 31st total of 1,277 shares. Approximately 0.1% of the shares of
The iShares Genomics Immunology and Healthcare ETF is invested in 49 companies involved in genomics, immunology and bioengineering. Compared with the biotechnology benchmark IBB, IDNA has value characteristics, but has greatly underperformed, losing over 20% since its inception. Among genomics-focused ETFs, PBE offers a relatively safer choice with better performance and lower volatility.
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February.
To use a holiday analogy, I have been checking lists and checking them twice to figure out which of next year's top disruptive investment themes are likely to be nice.